Portfolio of Gene Therapy Stocks
Here are 9 gene therapy stocks. See 10 Most Promising Gene Therapy Companies to Watch.
| 9 Portfolio of Gene Therapy Stocks | ||
|---|---|---|
Name & Return | Symbol | |
| Akouos | AKUS | |
| Beam Therapeutics | BEAM | |
| bluebird bio | BLUE | |
| Crispr Therapeutics | CRSP | |
| Editas Medicine | EDIT | |
| Intellia Therapeutics | NTLA | |
| Krystal Biotech | KRYS | |
| uniQure N.V. | QURE | |
| Verve Therapeutics | VERV | |
| Display Price Chart for each stock. | ||
| Display Dividend Chart for each stock. | ||
Portfolio Values
To inspect the performance of the Portfolio of Gene Therapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.The 5 stocks included in the portfolio computations are: BLUE, CRSP, EDIT, NTLA and QURE. The current value of the portfolio assumes that $2,000.00 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 4 stocks excluded from the portfolio computations because of insufficient price data are: AKUS, BEAM, KRYS and VERV.The current value of the $10,000 investment is $6,204. The percent return is -37.96%. The annualized return is -9.11%.
Related Portfolios
Portfolio of Gene Editing (CRISPR) Stocks